BTIG raised the firm’s price target on Guardant Health (GH) to $60 from $55 and keeps a Buy rating on the shares after its Q4 earnings beat and “solid guide”. Guardant had an excellent 2024 and investor sentiment has significantly shifted positive as the company has a number of key catalysts ahead here in 2025, the analyst tells investors in a research note. The firm has long thought that Shield is underappreciated, but now also believes that Reveal and its flagship G360 franchise are underappreciated as well, BTIG adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $56 from $49 at Guggenheim
- Guardant Health’s Promising Growth Prospects: Buy Rating Backed by Strong Revenue Guidance and Optimistic Projections
- Guardant Health’s Strong 2024 Growth and 2025 Outlook
- Guardant Health: Strong Buy Rating Driven by Surpassing Performance and Optimistic Growth Outlook
- Guardant Health options imply 9.3% move in share price post-earnings